Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)

This study has been completed.
Information provided by:
Merck Sharp & Dohme Corp. Identifier:
First received: May 2, 2002
Last updated: March 15, 2011
Last verified: March 2011

May 2, 2002
March 15, 2011
September 2001
Not Provided
HAMD-17 total score at week 8. Tolerability. [ Time Frame: at week 8 ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00035282 on Archive Site
CGI-I score at week 8, at least 50% reduction in the HAMD-17 total score, and Sheehan Disability Score at Week 8 [ Time Frame: at week 8 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)
A Double-Blind, Placebo- and Active-Controlled Acute and Extension Study of MK0869 in the Treatment of Patients With Major Depressive Disorder

A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.

The duration of treatment is 8 weeks.

Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Major Depressive Disorder
  • Drug: aprepitant
    Other Name: MK0869
  • Drug: Comparator: placebo (unspecified)
Not Provided
Liu KS, Snavely DB, Ball WA, Lines CR, Reines SA, Potter WZ. Is bigger better for depression trials? J Psychiatr Res. 2008 Jul;42(8):622-30. Epub 2007 Sep 7.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2003
Not Provided

Patients with Major Depressive Disorder

18 Years and older
Contact information is only displayed when the study is recruiting subjects
Not Provided
2006_401, Formally-103, MK0869-060
Not Provided
Vice President, Late Stage Development Group Leader, Merck Sharp & Dohme Corp
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP